399 related articles for article (PubMed ID: 28596938)
1. Genome-Edited T Cell Therapies.
Delhove JMKM; Qasim W
Curr Stem Cell Rep; 2017; 3(2):124-136. PubMed ID: 28596938
[TBL] [Abstract][Full Text] [Related]
2. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
4. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
5. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
[TBL] [Abstract][Full Text] [Related]
6. Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.
de Lima SCG; Fantacini DMC; Furtado IP; Rossetti R; Silveira RM; Covas DT; de Souza LEB
Adv Exp Med Biol; 2023; 1429():85-110. PubMed ID: 37486518
[TBL] [Abstract][Full Text] [Related]
7. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
8. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
[TBL] [Abstract][Full Text] [Related]
9. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
10. Emerging CRISPR/Cas9 applications for T-cell gene editing.
Preece R; Georgiadis C
Emerg Top Life Sci; 2019 May; 3(3):261-275. PubMed ID: 33523139
[TBL] [Abstract][Full Text] [Related]
11. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
12. Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells.
Cappabianca D; Li J; Zheng Y; Tran C; Kasparek K; Mendez P; Thu R; Maures T; Capitini CM; Deans R; Saha K
Front Bioeng Biotechnol; 2024; 12():1379900. PubMed ID: 38882639
[TBL] [Abstract][Full Text] [Related]
13. Genome editing of therapeutic T cells.
Qasim W
Gene Genome Ed; 2021 Dec; 2():None. PubMed ID: 34977824
[TBL] [Abstract][Full Text] [Related]
14. Multiplexed engineering and precision gene editing in cellular immunotherapy.
Biederstädt A; Manzar GS; Daher M
Front Immunol; 2022; 13():1063303. PubMed ID: 36483551
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
16. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.
Lau E; Kwong G; Fowler TW; Sun BC; Donohoue PD; Davis RT; Bryan M; McCawley S; Clarke SC; Williams C; Banh L; Irby M; Edwards L; Storlie M; Kohrs B; Lilley GWJ; Smith SC; Gradia S; Fuller CK; Skoble J; Garner E; van Overbeek M; Kanner SB
Cytotherapy; 2023 Jul; 25(7):750-762. PubMed ID: 37086241
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy to get on point with base editing.
Harbottle JA
Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
[TBL] [Abstract][Full Text] [Related]
20. The promise and potential pitfalls of chimeric antigen receptors.
Sadelain M; Brentjens R; Rivière I
Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]